abstract |
Including, but not limited to, myelosuppression caused by administration of a phosphate diester hydrolase 4 (PDE4) inhibitor in combination with other therapeutic agents, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, osteoarthritis, ankylosing spondylitis, and rheumatoid arthritis And methods of treating, preventing, or managing disorders. Pharmaceutical compositions, formulations, and kits suitable for use in the methods of the invention are also disclosed. |